Matthew R. Baldwin, MD, MS

Critical Care Medicine
Pulmonology
More specialties
Profile Headshot

Profile Navigation

Overview

Dr. Baldwin is a board-certified pulmonary and critical care physician and clinical investigator with a Masters in Biostatistics. Dr. Baldwin’s research aims to improve critical illness survivorship and spans three areas of study.

  • Epi-mechanistic research to endophenotype acute respiratory failure survivors and COVID survivors to elucidate mechanisms of physical impairment as therapeutic targets for improving long-term recovery.
  • Clinical and epidemiologic research with a focus on clinical risk prediction modeling and health disparities outcomes.
  • Novel palliative care interventions aimed at improving ICU survivorship. For example, chaplain-led communication-board-guided spiritual care for mechanically ventilated patients.

Areas of Expertise / Conditions Treated

  • Acute Respiratory Distress Syndrome (ARDS)
  • Critical Care
  • General Pulmonology
  • Intensive Care
  • Pulmonary Critical Care Medicine
  • Pulmonary Disease
  • Pulmonary Medicine
  • Respiratory Failure

Academic Appointments

  • Herbert Irving Assistant Professor of Medicine at CUMC

Hospital Affiliations

  • NewYork-Presbyterian / Columbia University Irving Medical Center
  • NewYork-Presbyterian Allen Hospital

Gender

  • Male

Schedule an Appointment

Connect Patient Portal

For existing patients, login to make an appointment, view documentation or contact your care provider.

Connect Sign In

Credentials & Experience

Education & Training

  • MD, Columbia University College of Physicians and Surgeons
  • Residency: Johns Hopkins Hospital
  • Fellowship: NewYork-Presbyterian Hospital/Columbia University Medical Center

Board Certifications

  • Critical Care Medicine
  • Internal Medicine
  • Pulmonary Disease Medicine

Honors & Awards

  • Phi beta Kappa
  • Alpha Omega Alpha
  • NIH loan repayment awardee
  • NIA K23 awardee
  • Department of Defense PRMP awardee

Research

Research Interests

  • Acute Respiratory Distress Syndrome (ARDS)
  • Acute Respiratory Failure
  • Chronic critical illness
  • Critical care outcomes after hospital discharge
  • Lung Transplantation
  • Measuring and treating frailty among elderly survivors of critical illness
  • Palliative care for chronically and critically ill

Grants

W81XWH2110217
04/01/2021-03/31/2025
Department of Defense, Peer Reviewed Medical Research Program
Title: Covid-19 Lung Injury, ARDS, and Thrombosis: Acute Disease and Long-Term Sub-Phenotypes.
Role: PI, Co-PI Christine Garcia, MD, PhD

COVID-19 Clinical Trial 
09/01/2020-08/30/2021
Apellis Pharmaceuticals
Title/Goal: A randomized, double-blind, vehicle-controlled, multi-center, study of APL-9 (second generation
complement-3 inhibitor) in mild to moderate acute respiratory distress syndrome due to COVID-19.
Role: Site PI

Selected Publications

Risk-stratification, phenotyping, and discovery of mechanisms that may represent therapeutic targets in acute respiratory failure survivors.

  • Baldwin MR, Pollack LR, Friedman RA, Norris SP, Javaid A, O'Donnell MR, Cummings MJ, Needham DM, Colantuoni E, Maurer MS, Lederer DJ. Frailty subtypes and recovery in older survivors of acute respiratory failure: a pilot study. Thorax. 2020; 76(4):350-359. PMID: 33298583. 
  • Rosenberg BJ, Hirano M, Quinzii CM, Colantuoni E, Needham DM, Lederer DJ, Baldwin MR. Growth differentiation factor-15 as a biomarker of strength and recovery in survivors of acute respiratory failure. Thorax. 2019; 74(11):1099-1101. PMID: 31534031; PMCID: PMC7043788.
  • Baldwin MR, Singer JP, Huang D, Sell J, Gonzalez WC, Pollack LR, Maurer MS, D'Ovidio FF, Bacchetta M, Sonett JR, Arcasoy SM, Shah L, Robbins H, Hays SR, Kukreja J, Greenland JR, Shah RJ, Leard L, Morrell M, Gries C, Katz PP, Christie JD, Diamond JM, Lederer DJ. Refining Low Physical Activity Measurement Improves Frailty Assessment in Advanced Lung Disease and Survivors of Critical Illness. Annals of the American Thoracic Society. 2017; 14(8):1270-9. PMID: 28398076; PMCID: PMC5566272.
  • Philpotts YF, Ma X, Anderson MR, Hua M, Baldwin MR. Health Insurance and Disparities in Mortality among Older Survivors of Critical Illness: A Population Study. Journal of the American Geriatrics Society. 2019; 67(12):2497-2505. PMID: 31449681; PMCID: PMC7208434.

Discovery of immunophenotypes of COVID-19 ARDS and pulmonary fibrosis sub-phenotypes of COVID-19 survivors.

  • Anderson MR, Geleris J, Anderson DR, Zucker J, Nobel YR, Freedberg D, Small-Saunders J, Rajagopalan KN, Greendyk R, Chae SR, Natarajan K, Roh D, Edwin E, Gallagher D, Podolanczuk A, Barr RG, Ferrante AW, Baldwin MR. Body Mass Index and Risk for Intubation or Death in SARS-CoV-2 Infection: A Retrospective Cohort Study. Annals of Internal Medicine. 2020; 173(10):782-790. PMID: 32726151; PMCID: PMC7397550.
  • Weisberg SP, Connors T, Zhu Y, Baldwin MR, Lin WH, Wontakal S, Szabo PA, Wells SB, Dogra P, Gray JI, Idzikowski E, Bovier F, Davis-Porada J, Matsumoto R, Li Poon MM, Chait MP, Mathieu C, Horvat B, Decimo D, Bitan ZC, La Carpia F, Ferrara SA, Mace E, Milner J, Moscona A, Hod EA, Porotto M, Farber DL. Antibody responses to SARS-CoV2 are distinct in children with MIS-C compared to adults with COVID-19. Nature Immunology. 2021; 22(1):25-31. PMID: 33154590; PMCID: PMC8136619.
  • Szabo PA, Dogra P, Gray JI, Wells SB, Connors TJ, Weisberg SP, Krupska I, Matsumoto R, Poon MML, Idzikowski E, Morris SE, Pasin C, Yates AJ, Ku A, Chait M, Davis-Porada J, Zhou J, Steinle M, Mackay S, Saqi A, Baldwin M, Sims PA, Farber DL. Interplay of respiratory and systemic immune responses in the pathogenesis of severe COVID-19. Immunity 2021 54(4):797-814. PMID: 33765436 PMCID: PMC7951561.
  • McGroder C, Zhang D, Choudhury M, Salvatore M, D’Souza B, Hoffman E, Wei Y, Baldwin MR*, Garcia CK*. Pulmonary Fibrosis Four Months after COVID-19 is Associated with Severity of Illness and Blood Leukocyte Telomere Length. Thorax. 2021; April 29: online ahead of print.*Co-senior authors. PMID: 33927016.

Determining the clinical-epidemiologic effects of COVID-19 therapeutics and outcomes.

  • Cummings MJ, Baldwin MR, Abrams D, Jacobson BA, Meyer BJ, Balough EM, Aaron JG, Claassen J, Rabbani LE, Hastie J, Hochman BR, Salazar-Schicchi J, Yip NH, Brodie D, O’Donnell MR. Epidemiology, clinical course, and outcomes, of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet. 2020;395(10239):1763-1770. PMID: 32442528; PMCID: PMC7237188
  • Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, Labella A, Manson DK, Kubin C, Barr RG, Sobieszczyk ME, Schluger NW. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. The New England Journal of Medicine. 2020; 382:2411-2418; PMID: 32379955 PMCID:PMC7224609.

For a complete list of publications, please visit PubMed.gov